Welcome to our dedicated page for Nano Labs SEC filings (Ticker: NA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding precise R&D costs for Nano Labs’ Flow Processing Unit or untangling its cryptocurrency asset footnotes can feel like searching for a single transistor on a wafer. Nano Labs insider trading Form 4 transactions, segment disclosures on high throughput computing chips, and risk factors tied to Chinese supply chains all sit inside hundreds of pages of technical prose. Investors often ask, “Where can I find Nano Labs quarterly earnings report 10-Q filing?” or “How is blockchain exposure reported in the 10-K?”—the answers are buried deep in EDGAR.
Stock Titan solves that complexity with AI-powered summaries that translate every line item into clear language. Whether you need Nano Labs Form 4 insider transactions real-time, Nano Labs proxy statement executive compensation details, or Nano Labs 8-K material events explained, our engine delivers instant context. Interactive tools highlight which paragraphs discuss FPU architecture capex, while side-by-side views compare gross-margin trends across filings. You’ll also receive real-time alerts the moment a Nano Labs executive stock transactions Form 4 hits the system, so you never miss a trade.
Use our platform to:
- Review Nano Labs annual report 10-K simplified—pinpoint crypto asset valuations without parsing accounting jargon.
- Dive into Nano Labs earnings report filing analysis to track near-memory HTC chip revenue quarter-over-quarter.
- Accelerate due diligence by understanding Nano Labs SEC documents with AI before markets react.
Nano Labs Ltd. Schedule 13G filings disclose that a group of related filers led by Anson Funds Management LP collectively beneficially own 1,808,440 Class A Ordinary Shares, representing 8.7% of the 20,712,924 outstanding Class A shares reported in the issuer's June 30, 2025 prospectus supplement. The reporting group includes Anson Management GP LLC, Anson Advisors Inc., and individuals Tony Moore, Amin Nathoo and Moez Kassam, with shared voting and dispositive power over the shares and no sole voting or dispositive power reported. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Nano Labs Ltd Schedule 13G discloses that Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B) and Waqas Khatri beneficially own 1,542,929 Class A ordinary shares, equal to 7.12% of the class as of June 30, 2025. That total comprises 590,548 shares held and 952,381 shares issuable on the exercise of warrants; the issuable shares are subject to a 9.99% beneficial ownership blocker. The filing cites 20,712,924 outstanding shares as of June 27, 2025, and reports sole voting and dispositive power over all 1,542,929 shares. The statement is signed by Waqas Khatri as Managing Member/Director for the reporting entities.
Nano Labs Ltd (NASDAQ: NA) filed Prospectus Supplement No. 4 to its May 2 2025 F-1 prospectus to register the potential resale of 652,174 Class A ordinary shares that may be issued upon exercise of outstanding warrants. The supplement incorporates three Form 6-K reports dated 2, 7 and 8 July 2025 and attaches the full warrant agreement, placement documents and Cayman legal opinions.
Key terms
- The warrants were issued in an April 11 2024 private placement and carry an $10.00 exercise price, initial exercise date of June 2025 and five-year term.
- The closing share price on 8 July 2025 was $7.86, below the exercise price, making near-term cash exercise unlikely.
- Exercise may be for cash or, under certain conditions, via cashless exercise. Anti-dilution provisions adjust the exercise price for stock splits, dividends, or dilutive issuances.
- No primary shares are being sold by the company; the selling shareholders will bear selling commissions. Nano Labs would receive proceeds only if warrants are exercised.
- The supplement reiterates high-risk disclosures and incorporates Cayman counsel’s opinion that the shares, when issued, will be validly issued, fully paid and non-assessable.
Investor implications
- Dilution potential: Full exercise would add ~2.3 % to current Class A float (based on ~28 m shares outstanding in last 20-F).
- Limited immediate impact: With the warrants currently out-of-the-money, cash inflow to Nano Labs is uncertain and resale volume depends on future share price performance.
- Legal clarity: Filing provides detailed warrant mechanics, tax opinions and confirms incorporation of recent 6-K disclosures into the registration statement.
FAQ
What is the current stock price of Nano Labs (NA)?
What is the market cap of Nano Labs (NA)?
